Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19839353 | 1.00 | GRIN2B (0.34) | GRIN2BGRIN2CLMNATDP1SMN1; SMN2 | |
| SCHEMBL19839355 | 1.00 | GRIN2B (0.34) | GRIN2BGRIN2CLMNATDP1SMN1; SMN2 | |
| SCHEMBL19853750 | 0.87 | GRIN2B (0.36) | GRIN2BGRIN2C | |
| SCHEMBL19854372 | 0.87 | GRIN2B (0.46) | GRIN2BGRIN2CLMNATDP1SMN1; SMN2 | |
| SCHEMBL19839370 | 0.87 | GRIN2B (0.46) | GRIN2BGRIN2CLMNATDP1SMN1; SMN2 | |
| SCHEMBL19839367 | 0.87 | GRIN2B (0.46) | GRIN2BGRIN2CLMNATDP1SMN1; SMN2 | |
| SCHEMBL19839379 | 0.85 | GRIN2B (0.38) | GRIN2BGRIN2C | |
| SCHEMBL19839374 | 0.85 | GRIN2B (0.38) | GRIN2BGRIN2C | |
| SCHEMBL19839410 | 0.77 | MME (0.37) | LMNASMN1; SMN2THRBHTT | |
| SCHEMBL21034552 | 0.77 | MME (0.37) | LMNASMN1; SMN2THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | GRIN2A, GRIN2B, GRIN1 | GRIN2B 2/4885GRIN2C 4/4885LMNA 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.